{"nctId":"NCT00357903","briefTitle":"Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials","startDateStruct":{"date":"1997-04"},"conditions":["Rheumatoid Arthritis"],"count":639,"armGroups":[{"label":"1","type":"OTHER","interventionNames":["Biological: Etanercept"]}],"interventions":[{"name":"Etanercept","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Previous enrollment in Immunex protocols\n* No clinically significant adverse events thought to be due to etanercept (TNFR:Fc) during previous treatment.\n* Negative serum pregnancy test not more than 14 days before the first dose of study drug in females of childbearing potential.\n* No more than one NSAID at a dose not greater than the maximum recommended dose and stable for at least two weeks prior to administration of etanercept (TNFR:Fc). Exclusion Criteria: - Previous receipt of TNFR:Fc (p55), antibody to TNF, anti-CD4 antibody, or diphtheria IL-2 fusion protein.\n* Receipt of investigational drugs or biologics (other than TNFR:Fc \\[p75\\]) within 1 month prior to the first dose of etanercept (TNFR:Fc) in this study.\n* Receipt of DMARDs or methotrexate (except patients from 16.0014) within two weeks prior to the first dose of etanercept (TNFR:Fc) in this study.\n* Receipt of cyclophosphamide within six months prior to the first dose of (etanercept (TNFR:Fc) in this study.\n* Receipt of cyclosporin within two weeks prior to the first dose of etanercept (TNFR:Fc) in this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total Exposure to Etanercept With Gaps","description":"Total participant exposure to etanercept (Enbrel) with gaps","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4033.07","spread":null},{"groupId":"OG001","value":"341.98","spread":null}]}]}]},{"type":"SECONDARY","title":"Dosing Period","description":"Duration of etanercept dosing","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2535.4","spread":"1433.77"},{"groupId":"OG001","value":"2153.6","spread":"1379.15"}]}]}]},{"type":"PRIMARY","title":"Total Exposure Adjusted Rate of Malignancies","description":"Exposure-adjusted rate of malignancies, excluding nonmelanoma skin cancers, occurring on study within 30 days of the last dose of etanercept","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.41","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"PRIMARY","title":"Total Exposure Adjusted Rate of Deaths","description":"Rate of deaths within 30 days of the last dose of etanercept, adjusted for total exposure to etanercept","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"PRIMARY","title":"Total Exposure Adjusted Rate of Serious Infectious Events","description":"Exposure-adjusted rate of serious infectious events (associated with hospitalization or IV antibiotics) occurring on study within 30 days of the last dose of etanercept","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.18","spread":null},{"groupId":"OG001","value":"3.22","spread":null}]}]}]},{"type":"PRIMARY","title":"Total Exposure Adjusted Rate of Lymphomas","description":"Rate of lymphomas occurring on study within 30 days of the last dose of etanercept, adjusted for total exposure to etanercept","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"PRIMARY","title":"Malignancy","description":"Occurrence of one or more malignancies on study within 30 days of the last dose of etanercept","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Lymphoma","description":"Occurrence of one or more lymphomas on study within 30 days of the last dose of etanercept","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Serious Infectious Event","description":"Occurrence of one or more serious infectious events within the participant on study within 30 days of the last dose of study medication. A serious infectious event is a serious adverse event that is infectious.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"PRIMARY","title":"Death","description":"Occurrence of death on study within 30 days of the last dose of etanercept","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Tender Joint Count","description":"Number of tender joints, as assessed by the investigator using criteria based on pressure and joint manipulation","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.55","spread":"10.97"},{"groupId":"OG001","value":"11.60","spread":"10.61"}]}]}]},{"type":"SECONDARY","title":"Swollen Joint Count","description":"Number of swollen joints","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.14","spread":"8.83"},{"groupId":"OG001","value":"11.93","spread":"11.86"}]}]}]},{"type":"SECONDARY","title":"Health Assessment Questionnaire Disability Index","description":"Health Assessment Questionnaire Disability Index (HAQ DI). This index is a weighted average of 24 items, each scored 0 (no difficulty) to 3 (unable to function).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"0.71"}]}]}]},{"type":"SECONDARY","title":"Childhood Health Assessment Questionnaire","description":"Childhood Health Assessment Questionnaire (CHAQ) disability index, having a range of 0 (no difficulty) to 3 (unable to do).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":"0.95"}]}]}]},{"type":"SECONDARY","title":"C-Reactive Protein","description":"C-reactive protein at month 12","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.37","spread":"1.85"},{"groupId":"OG001","value":"2.11","spread":"3.82"}]}]}]},{"type":"SECONDARY","title":"ACR20 at Month 3 in Adults","description":"American College of Rheumatology (ACR) 20, defined as a 20% improvement in both tender and swollen joints (78 joints) and a 20% improvement in 3 of 5 items (including physician and patient global assessments), in adults","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"372","spread":null}]}]}]},{"type":"SECONDARY","title":"JRA DOI 30 at Month 3 in Juveniles","description":"Juvenile Rheumatoid Arthritis Definition of Improvement 30 (JRA DOI 30), defined as a 30% improvement from baseline in 3 of 6 items (including Childhood Health Assessment Questionnaire, disease severity, overall well-being, and erythrocyte sedimentation rate) and a worsening of \\>30% in at most one of the remaining items.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Standardized Incidence Rate for All SEER Cancers","description":"Standardized incidence rate for all cancers tracked by the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) system.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"PRIMARY","title":"Total Exposure Adjusted Rate of Serious Adverse Events","description":"Rate of serious adverse events adjusted to total exposure to etanercept (events / exposure \\* 100)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.95","spread":null},{"groupId":"OG001","value":"12.87","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":293,"n":581},"commonTop":["Upper respiratory tract infection","Sinusitis","Headache","Bronchitis","Skin infection"]}}}